A cross‐sectional study of the <scp>FDA</scp> approved indications and supporting pivotal trials of small‐molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene-Reference-Cited by-同舟云学术

A cross‐sectional study of the FDA approved indications and supporting pivotal trials of small‐molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene

Published:2022-08-09 Issue:12 Volume:151 Page:2107-2114
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Huang Yafang¹^ORCID,Xiong Weiyi²,Ma Li³,Wu Hao¹

Affiliation:

1. School of General Practice and Continuing Education Capital Medical University Beijing China

2. Department II of Pharmaceuticals Surveillance and Evaluation National Center for ADR Monitoring Beijing China

3. Department of General Practice, Beijing Tiantan Hospital Capital Medical University Beijing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34222

Reference37 articles.

1. A compendium of mutational cancer driver genes

2. Implementing Genome-Driven Oncology

3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

4. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

5. Evaluating the evaluation of cancer driver genes

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early phase clinical trial played a critical role in the Food and Drug Administration–approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021;Journal of Clinical Epidemiology;2023-05